Edyta Leśniak, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński
{"title":"The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high-grade ovarian cancer.","authors":"Edyta Leśniak, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz, Andrzej Malinowski, Miłosz Wilczyński","doi":"10.5114/pm.2024.145949","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.</p><p><strong>Material and methods: </strong>Healthy controls and patients with high-grade serous carcinoma (<i>n</i> = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.</p><p><strong>Results: </strong>The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (<i>p</i> < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.</p><p><strong>Conclusions: </strong>This study supports the critical role of microRNA-196a in the progression of ovarian cancer.</p>","PeriodicalId":55643,"journal":{"name":"Przeglad Menopauzalny","volume":"23 4","pages":"180-184"},"PeriodicalIF":1.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11726191/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przeglad Menopauzalny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pm.2024.145949","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.
Material and methods: Healthy controls and patients with high-grade serous carcinoma (n = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.
Results: The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (p < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.
Conclusions: This study supports the critical role of microRNA-196a in the progression of ovarian cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
